Novel phospholipid-based topical formulations of tamoxifen: evaluation for antipsoriatic activity using mouse-tail model
暂无分享,去创建一个
[1] Bhupinder Singh,et al. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes , 2013, Journal of microencapsulation.
[2] A. Shukla,et al. Tamoxifen-loaded novel liposomal formulations: evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis , 2012, Journal of drug targeting.
[3] D. Paolino,et al. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. , 2012, International journal of pharmaceutics.
[4] Bhupinder Singh,et al. Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin , 2011, Journal of drug targeting.
[5] Bartosz A Grzybowski,et al. Vesicle-to-micelle oscillations and spatial patterns. , 2010, Langmuir : the ACS journal of surfaces and colloids.
[6] K. McMasters,et al. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer , 2010, Cancer.
[7] Carmen L. Lewis,et al. Effectiveness of a patient‐ and practice‐level colorectal cancer screening intervention in health plan members , 2010, Cancer.
[8] S. Bhushan,et al. Tamoxifen-encapsulated vesicular systems: cytotoxicity evaluation in human epidermal keratinocyte cell line. , 2009, Drug development and industrial pharmacy.
[9] J. Prat,et al. Uterine sarcomas: a review. , 2010, Gynecologic Oncology.
[10] Bhupinder Singh,et al. Phospholipid‐based formulation with improved attributes of coal tar , 2009, Journal of cosmetic dermatology.
[11] S. Ferrero,et al. Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. , 2008, Breast.
[12] R. Kumar,et al. Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: A review , 2005, AAPS PharmSciTech.
[13] R. Tripathi,et al. Drug-Induced Ocular Disorders , 2008, Drug safety.
[14] Bhupinder Singh Bhoop,et al. Tamoxifen in pluronic lecithin organogel: A novel topical approach for cancer treatment. , 2007 .
[15] R. Hayashi,et al. Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors , 2007, Oncogene.
[16] R. Barakat,et al. Comparison of uterine malignancies that develop during and following tamoxifen therapy. , 2006, Gynecologic oncology.
[17] Christopher P. Thomas,et al. Preferential π–π complexation between tamoxifen and borage oil/γ linolenic acid: transcutaneous delivery and NMR spectral modulation , 2005 .
[18] Amit Bhatia,et al. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. , 2004, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[19] P. Brown,et al. Should Tamoxifen Be Used in Breast Cancer Prevention? , 2004, Drug safety.
[20] W. Cunliffe,et al. Effect of crude coal tar in the mouse-tail model of psoriasis , 2004, Archives of Dermatological Research.
[21] G. Cevc,et al. Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes. , 2003, Biochimica et biophysica acta.
[22] S. Chan. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. , 2002, Seminars in oncology.
[23] G. Hortobagyi,et al. Progress in breast cancer chemoprevention. , 2002, Endocrine-related cancer.
[24] H. Hoffmann,et al. Lecithin Organogel with New Rheological and Scaling Behavior , 2001 .
[25] L. King,et al. Tamoxifen-induced remission of psoriasis. , 1999, Journal of the American Academy of Dermatology.
[26] G. Cevc. Overcoming the Skin Barrier with Artificial Smart Carriers of Drugs , 1999 .
[27] A. Jirillo,et al. Psoriasis and tamoxifen therapy: a case report. , 1996, Tumori.
[28] G. Cevc. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. , 1996, Critical reviews in therapeutic drug carrier systems.
[29] H. Jacobs,et al. Cyclical psoriatic arthritis responding to anti‐oestrogen therapy , 1993, The British journal of dermatology.
[30] T. Matthiesen,et al. A quantitative method for measuring antipsoriatic activity of drugs by the mouse tail test. , 1992, Skin pharmacology : the official journal of the Skin Pharmacology Society.
[31] M. Greaves,et al. Evaluation of a therapeutic concentration of dithranol in the mouse‐tail test , 1988, The British journal of dermatology.
[32] J. Pasqualini,et al. Estrogen and progesterone receptors in the fetal and newborn vagina of guinea pig: biological, morphological, and ultrastructural responses to tamoxifen and estradiol. , 1986, Endocrinology.
[33] J. Pasqualini,et al. Biological responses of tamoxifen in the fetal and newborn vagina and uterus of the guinea-pig and in the R-27 mammary cancer cell line. , 1986, Journal of steroid biochemistry.
[34] B. Ninham,et al. Micelles, vesicles and microemulsions , 1981 .
[35] A. Britten,et al. Evaluation of coal tar fractions for use in psoriasiform diseases using the mouse tail test , 1975, The British journal of dermatology.
[36] A. Britten,et al. Evaluation of coal tar fractions for use in psoriasiform diseases using the mouse tail test , 1975, The British journal of dermatology.